Company news

Immutep Ltd news in 2021

Immutep Ltd's news releases, calls and decks from 2021, newest first.

View company

Immutep Advances IMP761 Manufacturing

December 15, 2021

Good safety reported from 1st five patients in INSIGHT-003

December 1, 2021

Phase II TACTI-002 trial recruitment successfully completed

November 18, 2021

Immutep Global Webcast Slides to Discuss Clinical Results

November 16, 2021

Immutep announces publication of SITC 2021 posters

November 14, 2021

Immutep announces publication of SITC 2021 abstracts

November 9, 2021

Immutep granted Chinese Patent for eftilagimod alpha

November 2, 2021

Immutep receives EMA scientific advice for Phase 3 in MBC

October 28, 2021

Immutep Quarterly Activities Report & Appendix 4C

October 27, 2021

Immutep Receives A$3.4 million R&D French Tax Incentive

September 28, 2021

Recruitment of patients completed for Part B of TACTI-002

September 1, 2021

Immuteps partner, EOC Pharma, expands efti trial pipeline

August 30, 2021

Chinese patent granted for anti-LAG-3 antibody LAG525

August 26, 2021

INSIGHT-003 investigator-initiated trial - 1st patient dosed

August 4, 2021

Completion of Placement - Tranche 2

July 29, 2021

Completion of Share Purchase Plan

July 20, 2021

US FDA & IRB approves start of ph2b head & neck cancer trial

July 5, 2021

Efti to be evaluated in new triple combination therapy trial

June 21, 2021

Immutep secures commitments for A$60 million in a Placement

June 20, 2021

Immutep global webcast slides

June 9, 2021

Immutep Reveals a New anti-LAG-3 Research Program

June 7, 2021

Immutep Reports Positive Data from its TACTI-002 ph 2 trial

June 4, 2021

Immutep granted European patent for its LAG-3 candidate Efti

June 2, 2021

Immutep enters New Collaboration with Merck KGaA for Efti

May 31, 2021

Immutep granted Chinese patent for its LAG-3 candidate Efti

May 26, 2021

Operational Update

May 7, 2021

TACTI-002 & INSIGHT-004 data to be presented at ASCO

April 28, 2021

Immutep receives A$1,155,055 R&D Tax Incentive

April 16, 2021

Immutep achieves Fast Track designation for Efti from US FDA

April 7, 2021

Immutep announces European Patent Grant for LAG525

April 6, 2021

Immutep collaborates with MSD for phase 2b head & neck trial

March 15, 2021

S&P DJI Announces March 2021 Quarterly Rebalance

March 12, 2021

Immutep secures second US patent grant for eftilagimod alpha

March 9, 2021

Phase II study for eftilagimod alpha in COVID-19 advances

January 26, 2021

Ulcerative Colitis Phase II Study of GSK2831781 Discontinued

January 21, 2021

Recruitment of head & neck cancer patients completed for ph2

January 6, 2021

Decks in 2021